Ravenscroft Apothecary, Inc. DBA Ravenscroft Escentials

Warning LetterOpen

Ginger Ravenscroft Ravenscroft Apothecary, Inc. DBA Ravenscroft Escentials 351 NW Pleasant View Dr Grants Pass , OR 97526 United States ginger@ravenscroftescentials.com orders@ravenscroftescentials.comIssued Mar 12, 2021Center for Drug Evaluation and Research

View Letter

Source: FDA, published letter. FDA published this warning letter; View Letter opens FDA's copy.

Violations2

Issue DateMar 12, 2021

Product TypeDrugs

StatusOpen

Letter Details

Firm: Ravenscroft Apothecary, Inc. DBA Ravenscroft Escentials
Location: Ginger Ravenscroft Ravenscroft Apothecary, Inc. DBA Ravenscroft Escentials 351 NW Pleasant View Dr Grants Pass , OR 97526 United States ginger@ravenscroftescentials.com orders@ravenscroftescentials.com
FEI Number: N/A
Country: United States
Issue Date: March 12, 2021
Issuing Office: Center for Drug Evaluation and Research
Product Type: Drugs
Status: Open

Summary

Ravenscroft Apothecary, Inc. was selling four products—"Air Purify Aromamist," "Healer's Chai Aromatea & Breath Drops," "Elevation of Mind Aromamist," and "Rose Frequency Tongue Tincture"—with claims that they could mitigate, prevent, treat, diagnose, or cure COVID-19, violating section 505(a) of the FD&C Act by marketing unapproved new drugs. The products were also misbranded under section 502 of the FD&C Act, and their sale constituted prohibited introduction of drugs into interstate commerce under sections 301(a) and (d). The FDA conducted its review during the COVID-19 pandemic emergency declaration period, when the agency was implementing urgent enforcement measures to prevent false or unsubstantiated claims about disease treatments.

Ravenscroft Apothecary, Inc. DBA Ravenscroft Escentials FDA Warning Letter, March 12, 2021